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A 49-year-old man complained of dysuria and pollakisuria. The prostate was enlarged， and the 
serum level ofprostate specific antigen was within the normal range. Under the diagnosis ofbenign 
prostatic hypertrophy， transurethral resection of the prostate was performed. Unexpectedly， 
histopathological examination of the resected tissues revealed pure small cell carcinoma. The surum 
level of progastrin-releasing peptide (ProGRP) was slightly elevated. The cancer was clinically 
diagnosed as stage C. 
Pelvic radiotherapy combined with chemotherapy using cisplatin (CDDP) and etoposide (VP・16)
was started according to the treatment for limited small cell cancer ofthe lung. After one month， the 
serum level ofProGRP decreased to the normal range. After four months， the prostate was reduced in 
size without any findings of metastases on computed tomography， and prostate biopsy revealed no 
viable cancer cells. 
(Acta Urol. Jpn. 48: 97-100， 2002) 
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